KRAS and lung cancer: The selective KRAS inhibitor (KRASi) sotorasib, which specifically targets KRAS(G12C) by creating a stable covalent bond with a mutant cysteine residue, has been approved by the US Food and Drug Administration as a second-line treatment for locally advanced or metastatic non–small cell lung cancer carrying the KRAS(G12C) mutation (4).